SidneyAlexanderScudderMD
Oncology • Sacramento, CAProfessor, Internal Medicine, UC, Davis School of Medicine
Dr. Scudder is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4501 X Street
Sacramento, CA 95817Phone+1 916-734-3771
Summary
- Dr. Sidney Scudder, based in Sacramento, CA, is an experienced oncologist with a specialization in medical oncology. He obtained his degree from the University of Florida College of Medicine and completed his residencies at Stanford Health Care and Washington University in St. Louis School of Medicine. Dr. Scudder has made valuable contributions to the field of oncology with publications in reputable journals such as Lung Cancer and Gynecologic Oncology, which have collectively been cited by other publications 48 times.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1983 - 1985
Washington University in St. Louis School of MedicineResidency, 1980 - 1983
University of Florida College of MedicineClass of 1980
Certifications & Licensure
CA State Medical License 1983 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 34 citationsClinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studiesYi-Long Wu, Victor C. S. Lee, Chong-Kin Liam, Shun Lu, Keunchil Park
Lung Cancer. 2018-12-01 - 20 citationsDetection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe.Cleo Keppens, John F. Palma, Partha Das, Sidney A Scudder, Wei Wen
The Journal of Molecular Diagnostics. 2018-07-01 - 16 citationsA phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensit...Ignace Vergote, Russell J. Schilder, Charles H. Pippitt, Shirley Wong, Alan N. Gordon
Gynecologic Oncology. 2014-10-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
